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BACKGROUND: Little is known about risk factors for childhood rhabdomyosarcoma (RMS) and the histology-specific details are rare.
METHODS: Case–control studies formed by linking cancer and birth registries of California, Minnesota, New York, Texas and
Washington, which included 583 RMS cases (363 embryonal and 85 alveolar RMS) and 57966 randomly selected control subjects,
were analysed using logistic regression. The associations of RMS (overall, and based on embryonal or alveolar histology) with birth
weight across five 500g categories (from 2000 to 4500g) were examined using normal birth weight (2500–3999g) as a reference.
Large (490th percentile) and small (o10th percentile) size for gestational age were calculated based on birth weight distributions in
controls and were similarly examined.
RESULTS: High birth weight increased the risk of embryonal RMS and RMS overall. Each 500g increase in birth weight increased the
risk of embryonal RMS (odds ratio (OR)¼1.27, 95% confidence interval (CI)¼1.14–1.42) and RMS overall (OR¼1.18, 95%
CI¼1.09–1.29). Large size for gestational age also significantly increased the risk of embryonal RMS (OR¼1.42, 95%
CI¼1.03–1.96).
CONCLUSIONS: These data suggest a positive association between accelerated in utero growth and embryonal RMS, but not alveolar
RMS. These results warrant cautious interpretation owing to the small number of alveolar RMS cases.
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Rhabdomyosarcoma (RMS) is the commonest soft-tissue sarcoma
in children below 15 years, with half the cases occurring before the
age of 10 years (Ries, 1999). Owing to the early age of onset,
in utero exposures have been suggested to have a role in its
aetiology, including in utero X-ray exposure (Grufferman, 1991,
2009), maternal drug use (Grufferman et al, 1993, 1982), advanced
maternal age(Grufferman, 1991) and stillbirths (Ghali et al, 1992).
In addition, several familial syndromes (Diller et al, 1995; DeBaun
and Tucker, 1998; Samuel et al, 1999; Tekin et al, 2002; Meyer et al,
2004; Aoki et al, 2005; Gripp, 2005; Ferrari et al, 2007; Moschovi
et al, 2007; Trahair et al, 2007; Li and Fraumeni, 1969a,b) and a
larger prevalence of congenital malformations (Ruymann et al,
1988) among affected children suggest that genetic predisposition
may be important. However, collectively these factors account for
only a small fraction of cases.
High birth weight has been associated with several childhood
malignancies, and recent evidence suggests that accelerated intrau-
terine growth may increase RMS risk, although based on only 27
cases (Laurvick et al, 2008). Further, the two major histological
subtypes (embryonal and alveolar RMS) have distinct localisations,
ages of onset, incidence and survival trends (Ries, 1999; Ognjanovic
et al, 2009) and distinct tumour gene expression signatures
(Davicioni et al, 2006; Wachtel et al, 2006; Lae et al, 2007),
suggesting that their aetiologies may be distinct. Embryonal RMS is
characterised by earlier age of onset than alveolar RMS; the majority
of embryonal RMS cases are diagnosed in the first decade of life, with
more than half of cases occurring before the age of 5 years. As an
equal number of alveolar RMS is diagnosed in the first and second
decades of life (Ognjanovic et al, 2009), we hypothesised that factors
affecting in utero growth, resulting in high birth weight would be
more important in embryonal than in alveolar RMS.
To assess the role of birth characteristics and the risk of RMS
and its two major subtypes, we used pooled data from five states
(Minnesota, California, New York (excluding New York City),
Washington and Texas) with case–control data sets by having
linked cancer and birth registries (Spector et al, 2009).
MATERIALS AND METHODS
Institutional review board approvals were obtained from each
participating institution and State department of health. The
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yselection of cases and controls varied by state and has been
previously described in detail (Puumala et al, 2009). The age
range was 28 days to 14 years, except in California, wherein only
cases up to age 4 years were available. The contribution of cases
and controls by each state to this pooled analysis is shown in
detail in Table 1. Controls were matched to cases in all states on
birth year, whereas additional matching on sex was performed in
California and Texas (Table 1). Controls were frequency
matched, except in California, wherein individual matching was
used. The number of controls per case varied by state and ranged
from 1 to 10 controls per case. Children with documented Down’s
syndrome in their birth records were excluded from analyses
(n¼100), but possibly not completely, because such reporting
was not implemented in Texas before 1984 and in Washington
before 1989.
The information available for cases included RMS diagnoses and
the age of onset. Cases were classified according to the
International Classification of Childhood Cancer (ICCC-3), third
edition (Steliarova-Foucher et al, 2005) using the following
histology codes: 8910/3, embryonal RMS; 8991/3, alveolar RMS;
8900/3, not otherwise specified; 8901/3, pleomorphic; 8902/3,
mixed type; and 8912/3, spindle cell. In our analyses, RMS overall
included all six categories, whereas embryonal and alveolar RMS
were also analysed separately.
The perinatal characteristics available from birth records were
birth weight, gestational age, sex, birth order, plurality (singleton
or multiple birth), year of birth, parental age and race/ethnicity
and maternal years of education. Gestational age clinical estimate
was provided by each state, except California, which provided only
the date of last menstrual period (LMP) that was used for
gestational age calculation. Some states also provided the LMP
information; therefore, a combined gestational age variable was
developed that gave preference to the calculated estimate when
available and used clinical estimate otherwise. Gestational ages less
than 20 or more than 45 weeks were deemed implausible, as were
birth weights less than 350g, and were excluded from analyses.
Maternal education was available from all states only after 1992
and was, therefore, included in secondary analysis. Using birth
records data, we calculated size for gestational age based on the
distribution observed in controls (described below). Separate
distributions were used for males and females.
Birth weight categories were selected to distinguish very low
birth weight (o2000g), low birth weight (2000–2499g), normal
weight (2500–3999g), high birth weight (4000–4499g) and very
high birth weight (44500g). The very low birth weight category
was assigned higher than the standard cutoff at o1500g, because
only seven cases weighed less than 2000g. Normal birth weight was
used as a reference group for comparisons. Gestational age was
categorised as 20–36 (preterm), 37–40 (term) and 440 weeks
(post-term). Size for gestational age was analysed using an internal
standard (the distribution in controls). The tenth and ninetieth
percentiles were used as cut points for small for gestational age and
large for gestational age (LGA), respectively. We used this internal
standard rather than other published external standards because of
the large number of controls available and the long span of the
study. For plurality, we distinguished single vs multiple births.
Birth order was categorised as first, second, third, fourth or higher
order. Parental age categories consisted of o20, 20–24, 25–29,
30–34, and 435 years. Maternal education categories consisted of
o12, 12, 13–16, 417 years.
Statistical analysis
All analyses were carried out using SAS version 9.1 (Cary, NC,
USA). Unconditional logistic regression was used to calculate
adjusted odds ratios (OR) and 95% confidence intervals (CI) to
examine the associations between perinatal characteristics and
RMS and its two major subtypes. Individual matching in California
was broken for the purpose of pooled analysis. Results of analyses
in subgroups which had fewer than four (RMS overall) or two cases
(for RMS subtypes) were not reported. Risk estimates were
adjusted for available covariates. After adjustment for state/study
centre, the choice of other variables evaluated as possible
confounders included those known or suspected to be associated
with inappropriate fetal growth (Das and Sysyn, 2004; Valero De
Bernabe et al, 2004).
RESULTS
This study included a total of 583 RMS cases; of these, 363 were
embryonal and 85 alveolar RMS. The sex distribution varied by
subtype, with embryonal RMS affecting 30% more males than
females (Table 2). As this subtype comprised 62% of all RMS cases,
a similar proportion was observed for the entire group. The
proportion of mothers and fathers older than 35 years at child’s
birth was greater in cases than controls (data not shown).
However, mean age of mothers of RMS patients was similar to
controls (27.2 and 26.7 years, respectively), as were those of fathers
(30.2 and 29.7 years, respectively). Maternal and paternal ages were
highly correlated (Pearson’s correlation coefficient¼0.74). As
anticipated, the alveolar RMS cases were older on average, with
53% diagnosed at o4 years compared with 68% of embryonal
RMS cases. A similar proportion of cases and controls were born
from singleton or multiple pregnancies. The proportion of ‘other’
mothers (that is, not white, black or Asian race) was significantly
higher for embryonal RMS cases than controls.
Table 2 shows the associations between birth characteristics of
the child and RMS risk. The multivariate models included birth
year, state, maternal age, race, child’s sex, gestational age, plurality,
birth order and birth weight, and were adjusted for all other
covariates and matching factors. For parental characteristics, we
observed the previously reported (Grufferman et al, 1982)
association between maternal age over 35 years and increased
risk of RMS (OR¼1.35, 95% CI¼1.01–1.81), suggesting that
embryonal histology was driving this association (OR¼1.54,
95%CI¼1.08–2.19). A 1-year increase in maternal age was
associated with 3 and 4% increases in RMS overall and embryonal
RMS risk, respectively. Paternal age over 35 years was not
significantly associated with increased RMS risk; however, a 1-
year increase in paternal age lead to 2% increased risk of RMS
overall and embryonal RMS. For maternal race, a significant
Table 1 Details of information provided by each state in the pooled analysis
State Ages at diagnosis Years of diagnosis Years of birth RMS cases No. of controls Matching factors
Minnesota 28 days to 14 years 1988–2004 1976–2004 73 8735 Birth year
Washington 28 days to 14 years 1980–2004 1980–2004 74 23728 Birth year, sex
California 28 days to 4 years 1988–1997 1983–1997 136 8730 Birth year, sex
New York 28 days to 14 years 1985–2001 1970–2001 152 12041 Birth year
Texas 28 days to 14 years 1990–1998 1975–1998 148 4732 Birth year
Abbreviation: RMS¼rhabdomyosarcoma.
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race, reflecting non-white, non-black or non-Asian population,
such as Hispanic or American Indians, was observed. As this is a
very heterogeneous category with only 11 embryonal RMS cases, it
probably represents a chance finding.
Higher birth order was inversely associated with risk of RMS
overall and embryonal RMS, but not alveolar RMS. Compared with
the first-born child, RMS point estimate for second-born child was
OR¼0.82 (95% CI¼0.67–1.00) and for third-born child it was
OR¼0.70 (95%CI¼0.54–0.91). This reduced risk reflects the
significant associations with birth order observed for embryonal
RMS, whereas no associations were observed for alveolar RMS
(Table 2).
Higher birth weight, however, was associated with increased risk
of RMS overall and embryonal RMS, with OR¼1.19 (95%
CI¼1.09–1.29) and OR¼1.27 (95% CI¼1.14–1.42) per 500g
increase in birth weight, respectively. Despite the trend, none of
the individual categories showed a significant association with
these risks. Only two alveolar RMS cases had birth weights below
normal (o2500g); hence, we could only compare cases with
normal birth weight (o4000g) (reference) with those with high
birth weight (4000–4500g), and we observed no association. We
observed no association with gestational age for RMS or either of
its subtypes. The majority of cases born preterm were between 32
and 36 weeks gestation, and only two cases were born before 32
weeks.
Table 2 Perinatal characteristics, including birth weight and the risk of childhood RMS, and its two major subtypes (embryonal RMS and alveolar RMS)
All RMS Embryonal RMS Alveolar RMS
Variable OR
a (N) 95% CI OR
a (N) 95% CI OR
a (N) 95% CI
Maternal race
White Ref (494) Ref (312) Ref (69)
Black 0.93 (43) 0.67–1.29 0.76 (22) 0.48–1.21 1.43 (9) 0.70–2.92
Asian 1.01 (26) 0.66–1.54 1.02 (18) 0.61–1.71 (3)
Other 1.44 (14) 0.83–2.51 2.04 (11) 1.09–3.84 (2)
Maternal age (years)
o20 0.84 (65) 0.62–1.15 0.70 (35) 0.46–1.05 1.08 (11) 0.50–2.33
20–24 0.81 (131) 0.64–1.02 0.78 (79) 0.58–1.05 0.91 (21) 0.51–1.64
25–29 Ref (188) Ref (118) Ref (28)
30–34 1.06 (131) 0.84–1.33 1.05 (83) 0.78–1.41 0.77 (15) 0.40–1.48
X35 1.35 (68) 1.01–1.81 1.54 (48) 1.08–2.19 1.27 (10) 0.60–2.69
Per 1-year increase 1.03 1.01–1.04 1.04 1.02–1.06 1.01 0.97–1.05
Paternal age
b (years)
o20 0.84 (17) 0.49–1.44 0.50 (7) 0.22–1.15 2.57 (5) 0.83–7.98
20–24 0.75(74) 0.56–1.00 0.72 (46) 0.50–1.04 1.26 (11) 0.58–2.76
25–29 Ref (158) Ref (102) Ref (17)
30–34 1.04 (139) 0.82–1.32 1.01 (86) 0.75–1.36 1.70 (23) 0.88–3.27
X35 1.21 (119) 0.94–1.56 1.24 (77) 0.90–1.69 1.82 (18) 0.90–3.68
Per 1-year increase 1.02 1.01–1.03 1.02 1.00–1.04 1.02 0.98–1.06
Child’s sex
Male 1.27 (348) 1.07–1.51 1.29 (221) 1.04–1.60 1.19 (47) 0.77–1.85
Female Ref (235) Ref (142) Ref (38)
Gestational age
p36 weeks 1.02 (42) 0.71–1.45 1.02 (26) 0.65–1.60 0.92 (7) 0.42–2.04
37–40 weeks Ref (349) Ref (218) Ref (52)
440 weeks 0.98 (173) 0.81–1.18 0.94 (105) 0.74–1.19 0.93 (24) 0.56–1.53
Plurality
Single birth Ref (570) Ref (356) (82)
Multiple birth 1.32 (13) 0.74–2.36 1.13 (7) 0.52–2.48 (3)
Birth order
First Ref (261) Ref (170) Ref (34)
Second 0.82 (178) 0.67–1.00 0.72 (105) 0.55–0.92 1.01 (25) 0.59–1.74
Third 0.70 (82) 0.54–0.91 0.57 (48) 0.40–0.80 1.23 (15) 0.64–2.34
Fourth + 0.75 (59) 0.55–1.02 0.69 (38) 0.47–1.01 1.12 (11) 0.51–2.48
Birth weight
o2000g 0.52 (7) 0.22–1.24 0.59 (4) 0.20–1.71 (1)
2000–2499g 0.66 (15) 0.38–1.14 0.67 (9) 0.33–1.35 (1)
2500–3999g Ref (476) Ref (294) Ref
c (75)
4000–4499g 1.08 (64) 0.82–1.42 1.21 (44) 0.87–1.69 0.48 (5) 0.19–1.19
X4500g 1.21 (15) 0.70–2.08 1.55 (11) 0.84–2.86 (2)
Per 500g increase 1.18 1.09–1.29 1.27 1.14–1.42 0.92 0.74–1.14
Abbreviations: CI¼confidence interval; OR¼odds ratio; RMS¼rhabdomyosarcoma.
aAdjusted for birth year, state, maternal age, maternal race, child’s sex, plurality and birth
order.
bAdjusted for birth year, state, maternal race, child’s sex, plurality, gestational age, birth weight and birth order.
cBirth weight o4000g was used as a reference and
compared with birth weight X4000g. Terms given in bold mark statistically significant results.
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accelerated fetal growth, we calculated size for gestational age as a
surrogate measure for accelerated fetal growth (Table 3). Being
LGA was associated with increased risk of RMS that reached
statistical significance for embryonal RMS (OR¼1.43, 95%
CI¼1.03–1.96) only.
Given the different control–case ratios in participating states,
sensitivity analyses were also conducted to determine whether the
number of controls per case affected the observed ORs. Limiting
the control number to one per case did not appreciably affect the
results in the main analysis (data not shown).
DISCUSSION
Children whose birth weight was high had an increased risk of
RMS overall and of embryonal RMS in particular. Trend analysis
showed that the birth weight increase per 500g increment
increased the odds of RMS and its embryonal subtype. The
examination of size for gestational age showed that LGA babies
had increased risk of developing embryonal RMS, whereas no
associations between birth weight alone or birth weight for
gestational age were observed for alveolar RMS. Our results
support the hypothesis that the two major RMS subtypes,
embryonal and alveolar RMS, have different aetiologies. The
associations with RMS overall primarily reflected the associations
observed for embryonal RMS, as the majority of cases belonged to
this subtype.
This is the first study to show that accelerated in utero growth,
measured by higher than expected weight for gestational age,
increases the risk of embryonal RMS. The only previous study of
relevance suggested an increased risk with increasing birth weight
and intrauterine growth (Laurvick et al, 2008), but the small
sample size precluded precise estimates. We and others have not
only shown that high birth weight increases the risk of RMS
thereby extending the associations reported for childhood cancers,
including leukaemia (Caughey and Michels, 2009), brain tumours
(Harder et al, 2008) and Wilms tumour (Schuz et al, 2001), but
also directly linked it to the extent of growth in utero. Our study
supports the view that size for gestational age provides insight
beyond that of birth weight per se (Laurvick et al, 2008) and can
identify new high-risk groups (Schuz et al, 2001). We observed no
association between gestational age and RMS risk, which may also
reflect the fact that only 26 embryonal and 7 alveolar RMS cases
were born prematurely, spread across 5 weeks before term (32–36
weeks), whereas only two RMS cases were born very prematurely
(more than 5 weeks).
Temporal trends in fetal growth show that the birth weight of
term infants has increased over the last two decades of the
previous century (Kramer et al, 2002), attributed primarily to
rising maternal pre-pregnancy BMI, greater gestational weight gain
and more prevalent gestational diabetes. These maternal anthro-
pometric factors affect maternal basal metabolic rates and increase
insulin-like growth factor-1 (IGF-1) levels, which lead to larger
fetal size (Chellakooty et al, 2004; Lof et al, 2005). Insulin-like
growth factors have a major role in fetal growth and development,
whereas their mitotic and anti-apoptotic properties can also
enhance tumour growth and may underlie the association between
larger fetal size and increased childhood cancer risk (Greaves,
2002). Indeed, an aetiological role of IGFs has been proposed for
embryonal RMS, in which chromosomal deletions, which fre-
quently affect the area of imprinted genes, including IGF-2, lead to
aberrant IGF-2 expression (Scrable et al, 1989; Rainier et al, 1993).
Beckwith–Wiedemann syndrome is associated with fetal over-
growth resulting from loss of imprinting in the IGF-2-containing
region on chromosome 11, and this syndrome increases RMS risk
(Dagher and Helman, 1999). Therefore, the differences between
embryonal and alveolar RMS risk associated with fetal growth may
partly reflect differences in underlying genetic predispositions
likely to be reflected in different growth patterns.
We also found that RMS cases were more likely to be first born,
as increasing birth order was associated with progressively
decreasing RMS risk owing to the embryonal subtype; no
association was observed for alveolar RMS. The similar findings
observed in childhood leukaemia prompted the suggestion that
later exposures to infections, an established risk factor for
leukaemia, may have been more frequent among the first-born
children (Schuz et al, 2001). Although no direct associations
between infections and RMS have been reported, maternal or
child’s antibiotic use was associated with increased risk of RMS
(Grufferman et al, 1982; Hartley et al, 1988), something we were
not able to evaluate. However, whether these associations were
confined to embryonal RMS and to first-born children only was
not examined.
We confirmed previously reported associations with increasing
maternal age, and have shown that this is significant for embryonal
histology only. In addition, we have observed that each 1-year
increase in paternal age is associated with a slight, but significant,
increase in RMS overall and embryonal RMS risk. Maternal
education was not associated with RMS risk, overall or by
subtype; however, this may be due to the limited availability of
this variable.
The main limitations of this study include multiple comparisons
and potential measurement error in the birth certificate data.
Although maternal age, birth weight, birth order and plurality have
been shown to be accurate in validation studies (Northam and
Knapp, 2006), gestational age reporting is likely to be less reliable
on birth certificates. Moreover, this was assessed by two different
methods depending on the state, which increased the complexity of
analysis and potentially introduced further error, though we have
no reason to suspect that this would have been differential.
Multivariate analyses were adjusted for potential confounders.
However, owing to categorisation of the variables, some residual
confounding may have remained. Strengths include that this was
population based and, therefore, avoided referral-type biases from
single-center studies or from those relying on subjects only
identified in clinical trials. In addition, the ascertainment of
exposures preceded diagnosis, thereby avoiding any reporting bias
by case–control status.
Our study further supports the view that embryonal RMS may
be associated with growth characteristics, suggesting that acceler-
ated in utero growth may have an important role. However,
caution is warranted in interpreting the results related to alveolar
and other RMS histology subtypes, given their small numbers, and
further studies are needed.
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Table 3 Associations between size for gestational age and RMS risk
All RMS Embryonal RMS Alveolar RMS
Variable OR 95% CI OR 95% CI OR 95% CI
Size for gestational age
a
Small 0.91 0.68–1.23 0.91 0.62–1.33 0.94 0.45–1.96
Average Ref Ref Ref
Large 1.22 0.93–1.61 1.42 1.03–1.96 0.93 0.42–2.03
Abbreviations: CI¼confidence interval; OR¼odds ratio; RMS¼rhabdomyosarco-
ma.
aAdjusted for birth year, state, maternal age, maternal race, child’s sex, plurality
and birth order. Terms given in bold mark a statistically significant result.
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